-
May 5, 2024 | 
jacc.org | Alexandra J. Lansky |Daniel Grubman |Michael Dwyer |Robert Zivadinov
References1. "The problem with asymptomatic cerebral embolic complications in vascular procedures: what if they are not asymptomatic?"J Am Coll Cardiol . 2012;60:17: 1614-1616. 2. "Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis". Eur Heart J . 2019;40:38: 3143-3153. 3. "STS-ACC TVT registry of transcatheter aortic valve replacement". J Am Coll Cardiol . 2020;76:21: 2492-2516. 4.
-
Jan 13, 2024 | 01473-3/fulltext?dgcid=twitter_organic_seminar24_lancet&hss_channel=tw-27013292&sz=64)
thelancet.com | Stefan Bittner |Robert Zivadinov |Sarah A. Morrow |Ralph HB Benedict
Multiple sclerosis - The Lancet
-
Nov 9, 2023 | 
journals.sagepub.com | Stefano Ziccardi |Tom Fuchs |Michael Dwyer |Robert Zivadinov
Get full access to this articleView all access and purchase options for this article. Data availability statementThe data that support the findings of this study are available from the corresponding author upon reasonable request. References1. Benedict RHB, Amato MP, DeLuca J, et al. Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues. Lancet Neurol 2020; 19(10): 860–871. 2. Prouskas SE, Schoonheim MM, Huiskamp M, et al.
-
Nov 7, 2023 | 01473-3/abstract?hss_channel=tw-27013292&dgcid=twitter_organic_seminar24_lancet&sz=64)
thelancet.com | Stefan Bittner |Robert Zivadinov |Sarah A. Morrow |Ralph HB Benedict
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
Aug 22, 2023 | 
neurologylive.com | Robert Zivadinov
WATCH TIME: 3 minutes"This study focuses on a unique cohort of patients with early MS and reaffirms the prevalence of cognitive impairment even in this population, urging a conversation about cognitive decline and its management."Multiple sclerosis (MS), a complex disease of the central nervous system (CNS), can cause permanent disability in patients living with the condition.
-
Aug 22, 2023 | 
hindawi.com | Alok Bhan |Cecilie Varming Jacobsen |Ingvild Dalen |Guido Alves |Niels Bergsland |Kjell-Morten Myhr | +2 more
Introduction. Cognitive impairment is an important contributor to disability in multiple sclerosis (MS). Disconnection of neuronal circuits due to axonal injury is probably an important underlying mechanism for this disability. Neurofilament light chain (NfL) is a neuron-specific constituent of axons and has gained increasing attention as a biomarker of axonal injury. Objective.
-
Jul 9, 2023 | 
neurologylive.com | Robert Zivadinov
WATCH TIME: 5 minutesOzanimod (Zeposia; BMS), an FDA-approved sphingosine 1-phosphate (S1P) receptor modulator for multiple sclerosis (MS), is a selective agent that offers easier use for patients with comorbidities.
-
Mar 6, 2023 | 
neurologylive.com | Robert Zivadinov
WATCH TIME: 5 minutesMRI scans, the standard for tracking disease progression in multiple sclerosis (MS), can provide several benefits, including monitoring lesions in the brain and spinal cord, help determine the types of lesions, and help guide patient treatment decisions. Despite the expansion in therapeutics for MS, a subgroup of patients will develop rapid and progressive disability at a relatively young age.
-
Mar 2, 2023 | 
neurologylive.com | Robert Zivadinov
WATCH TIME: 4 minutesA collaboration between The Boston Home (TBH) and the University at Buffalo (UB), the CASA-MS study is an ongoing trial understanding severe multiple sclerosis (MS) through imaging, clinical, cognitive, and laboratory features.
-
Feb 28, 2023 | 
neurologylive.com | Robert Zivadinov
WATCH TIME: 4 minutesWhile there have been advances in the treatment of relapsing forms of multiple sclerosis (MS), understanding why some patients continue to progress at rapid rates remains a critical unmet need. A progressive disease course—either primary progressive MS at onset or transitioning to secondary progressive MS—is the dominant factor affecting MS-related neurologic disability accumulation.
